Patricia M. Drake - Jun 1, 2021 Form 4 Insider Report for Sesen Bio, Inc. (CARM)

Signature
/s/ Mark R. Sullivan, as attorney-in-fact
Stock symbol
CARM
Transactions as of
Jun 1, 2021
Transactions value $
$0
Form type
4
Date filed
6/3/2021, 06:45 PM
Next filing
Nov 12, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CARM Employee Stock Option (Right to Buy) Award $0 +1M $0.00 1M Jun 1, 2021 Common Stock 1M $3.87 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to such option shall vest on the first anniversary of the date of grant of the option and an additional 6.25% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until the fourth anniversary of the date of grant of the option. Based on market analysis by Radford of public, pre-commercial biopharmaceutical companies, the compensation committee of Sesen Bio, Inc ("the Company"), recommended to the Company's board of directors, and the board of directors approved, the grant to the reporting person.